EditForce
Business Services · Japan · <25 Employees
View Company Info for Free
About
Headquarters
9f saiwai bldg 1-3-1 Uchisaiwai-cho, Chiyoda-ku...Phone Number
+81 5054445960Website
www.editforce.co.jpRevenue
<$5 MillionIndustry
Who is EditForce
EditForce Org Chart
Is EditForce your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Click to see if EditForce had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at EditForce
EditForce, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once EditForce has new funding data
Check if EditForce has recently received funding, and reach out quickly before it becomes old news!
Check out if EditForce is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on EditForce recently announced quarterly report
Product Launch: Get notified when EditForce launches new products
Recommended Actions
Find VP level buyers at EditForce
Find 3 more new buyers
EditForce Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
EditForce Tech Stack
A closer look at the technologies used by EditForce
Most Recent Scoops
EditForce News & Media
EditForce Realizes RNA-editing Technology of "U-to-C"
FUKUOKA, Japan, Oct. 18, 2022 /PRNewswire/ -- EditForce, Inc. (hereinafter "EditForce"), headquartered in Fukuoka, Japan, has realized the world's first RNA-editing technology that enables RNA-editing bases to be changed from "U" to "C," and demonstrated that this technology works even in...EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement
FUKUOKA, Japan, July 5, 2022 /PRNewswire/ -- EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; hereinafter "EditForce") has entered into a License Agreement (hereinafter "Agreement") with Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka, Representative...Newton Biocapital invests in EditForce to develop a unique DNA/RNA editing platform based on PPR protein technology
TOKYO, JAPAN, July 1, 2021 /EINPresswire.com/ -- Newton Biocapital (“Newton”), a life sciences investment fund active in Europe and Japan and focused on the treatment and prevention of chronic diseases, has announced its follow-up investment in EditForce …
Frequently Asked Questions Regarding EditForce
Launched in 2015 at Kyushu University, EditForce is developing a proprietary DNA/RNA editing technology known as PPR protein platform technology. With the vision of "New Tools Lead to a New World", the company is committed to offering this new DNA/RNA manipulating tool to a wide range of bio-related industries including medical, chemical, and agric... Read More